Yohimbine HCL 2,5 mg YN

Description

Yohimbine HCL 2,5 mg YN — yohimbine from the manufacturer at 2.5 mg. Alpha-2 adrenergic antagonist enabling beta-adrenergic fat mobilisation in stubborn adipose regions. Pre-cardio fasted timing optimises effect.

Key Benefits

• α2-adrenergic antagonist — blocks fat-cell inhibitory signalling
• Targeted fat mobilisation in stubborn areas (lower abdomen, hips)
• Fasted-state dosing for maximum effect
• Oral once-daily; anxiety-prone users should avoid
• Standalone or stacked with clenbuterol for aggressive cutting
• Each unit dosed at 5 mg — see Recommended Dosage below for protocol-specific intake

How It Works

α2-adrenergic receptor antagonist. α2 receptors on adipocytes inhibit lipolysis — blocking them un-caps fat mobilisation, especially in “stubborn” fat depots (lower body, abdomen) that are α2-dense. Fasted state amplifies effect because insulin blunts lipolysis.

Pharmacokinetics

Plasma half-life approximately 36 minutes — short burst effect. Pre-workout dosing only. Oral bioavailability moderate.

Potential Side Effects

Anxiety, jitteriness, blood-pressure spikes. Not for anxiety-prone users. Avoid with SSRIs, MAOIs, or caffeine overload. Tachycardia during workout normal but monitor.

Cycle & Stacking Guide

Pre-fasted-cardio dosing during cutting phases, 4–6 weeks. Stack with caffeine (with tolerance) or clenbuterol for aggressive fat-loss. Not a mass-phase compound.

Storage & Handling

Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.